Literature DB >> 24210501

Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain.

Young Jun Seo1, Lisa Muench, Alicia Reid, Jinzhu Chen, Yeona Kang, Jacob M Hooker, Nora D Volkow, Joanna S Fowler, Sung Won Kim.   

Abstract

Histone deacetylases (HDACs) regulate gene expression by inducing conformational changes in chromatin. Ever since the discovery of a naturally occurring HDAC inhibitor, trichostatin A (TSA) stimulated the recent development of suberoylanilide (SAHA, Zolinza®), HDAC has become an important molecular target for drug development. This has created the need to develop specific in vivo radioligands to study epigenetic regulation and HDAC engagement for drug development for diseases including cancer and psychiatric disorders. 6-([(18)F]Fluoroacetamido)-1-hexanoicanilide ([(18)F]FAHA) was recently developed as a HDAC substrate and shows moderate blood-brain barrier (BBB) permeability and specific signal (by metabolic trapping/or deacetylation) but rapid metabolism. Here, we report the radiosynthesis of two carbon-11 labeled candidate radiotracers (substrate- and inhibitor-based radioligand) for HDAC and their evaluation in non-human primate brain. PET studies showed very low brain uptake and rapid metabolism of both labeled compounds but revealed a surprising enhancement of brain penetration by F for H substitution when comparing one of these to [(18)F]FAHA. Further structural refinement is needed for the development of brain-penetrant, metabolically stable HDAC radiotracers and to understand the role of fluorine substitution on brain penetration. Published by Elsevier Ltd.

Entities:  

Keywords:  Brain; Brain permeability; Carbon-11; Epigenetics; Positron emission tomography; SAHA

Mesh:

Substances:

Year:  2013        PMID: 24210501      PMCID: PMC4007514          DOI: 10.1016/j.bmcl.2013.10.038

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  26 in total

1.  Improved solution- and solid-phase preparation of hydroxamic acids from esters.

Authors:  Chih Y Ho; Eric Strobel; Janet Ralbovsky; Robert A Galemmo
Journal:  J Org Chem       Date:  2005-06-10       Impact factor: 4.354

2.  The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.

Authors:  Brian M Zeglis; NagaVaraKishore Pillarsetty; Vadim Divilov; Ronald A Blasberg; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2011-03-03       Impact factor: 2.408

3.  A new antifungal antibiotic, trichostatin.

Authors:  N Tsuji; M Kobayashi; K Nagashima; Y Wakisaka; K Koizumi
Journal:  J Antibiot (Tokyo)       Date:  1976-01       Impact factor: 2.649

4.  Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA.

Authors:  Hsin-Hsien Yeh; Mei Tian; Rainer Hinz; Daniel Young; Alexander Shavrin; Uday Mukhapadhyay; Leo G Flores; Julius Balatoni; Suren Soghomonyan; Hwan J Jeong; Ashutosh Pal; Rajesh Uthamanthil; James N Jackson; Ryuichi Nishii; Hiroshi Mizuma; Hirotaka Onoe; Shinya Kagawa; Tatsuya Higashi; Nobuyoshi Fukumitsu; Mian Alauddin; William Tong; Karl Herholz; Juri G Gelovani
Journal:  Neuroimage       Date:  2012-09-17       Impact factor: 6.556

Review 5.  Histone deacetylase inhibitors: an attractive strategy for cancer therapy.

Authors:  Jiyang Li; Guangqiang Li; Wenqing Xu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 6.  Epigenetic chemical probes.

Authors:  S Müller; P J Brown
Journal:  Clin Pharmacol Ther       Date:  2012-10-24       Impact factor: 6.875

7.  Efficient radiosynthesis of carbon-11 labelled uncharged Thioflavin T derivatives using [11C]methyl triflate for beta-amyloid imaging in Alzheimer's Disease with PET.

Authors:  C Solbach; M Uebele; G Reischl; H-J Machulla
Journal:  Appl Radiat Isot       Date:  2005-04       Impact factor: 1.513

8.  Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.

Authors:  Stacy W Remiszewski; Lidia C Sambucetti; Peter Atadja; Kenneth W Bair; Wendy D Cornell; Michael A Green; Kobporn Lulu Howell; Manfred Jung; Paul Kwon; Nancy Trogani; Heather Walker
Journal:  J Med Chem       Date:  2002-02-14       Impact factor: 7.446

Review 9.  Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.

Authors:  Giuseppe Giannini; Walter Cabri; Caterina Fattorusso; Manuela Rodriquez
Journal:  Future Med Chem       Date:  2012-07       Impact factor: 3.808

10.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

View more
  18 in total

1.  Targeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT imaging of NNK-treated A/J mice model.

Authors:  Wayland Tang; Sharon A Kuruvilla; Valentin Galitovskiy; Min-Liang Pan; Sergei A Grando; Jogeshwar Mukherjee
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

Review 2.  Epigenetics and nutritional environmental signals.

Authors:  Elizabeth A Mazzio; Karam F A Soliman
Journal:  Integr Comp Biol       Date:  2014-05-26       Impact factor: 3.326

3.  Using Protein-Confined Proximity To Determine Chemical Reactivity.

Authors:  Tomonori Kobayashi; Christian Hoppmann; Bing Yang; Lei Wang
Journal:  J Am Chem Soc       Date:  2016-11-04       Impact factor: 15.419

4.  Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors.

Authors:  Young Jun Seo; Yeona Kang; Lisa Muench; Alicia Reid; Shannon Caesar; Logan Jean; Florence Wagner; Edward Holson; Stephen J Haggarty; Philipp Weiss; Payton King; Pauline Carter; Nora D Volkow; Joanna S Fowler; Jacob M Hooker; Sung Won Kim
Journal:  ACS Chem Neurosci       Date:  2014-05-21       Impact factor: 4.418

5.  Kinetic Analysis and Quantification of [¹¹C]Martinostat for in Vivo HDAC Imaging of the Brain.

Authors:  Hsiao-Ying Wey; Changning Wang; Frederick A Schroeder; Jean Logan; Julie C Price; Jacob M Hooker
Journal:  ACS Chem Neurosci       Date:  2015-03-25       Impact factor: 4.418

6.  Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors.

Authors:  Seiya Hiranaka; Yuma Tega; Kei Higuchi; Toshiki Kurosawa; Yoshiharu Deguchi; Mayumi Arata; Akihiro Ito; Minoru Yoshida; Yasuo Nagaoka; Takaaki Sumiyoshi
Journal:  ACS Med Chem Lett       Date:  2018-08-23       Impact factor: 4.345

Review 7.  A philosophy for CNS radiotracer design.

Authors:  Genevieve C Van de Bittner; Emily L Ricq; Jacob M Hooker
Journal:  Acc Chem Res       Date:  2014-10-01       Impact factor: 22.384

8.  Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain.

Authors:  Robin Bonomi; Uday Mukhopadhyay; Aleksandr Shavrin; Hsien-Hsien Yeh; Anjoy Majhi; Sajeewa W Dewage; Amer Najjar; Xin Lu; G Andrés Cisneros; William P Tong; Mian M Alauddin; Ren-Shuan Liu; Thomas J Mangner; Nashaat Turkman; Juri G Gelovani
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

9.  In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs.

Authors:  Changning Wang; Frederick A Schroeder; Hsiao-Ying Wey; Ronald Borra; Florence F Wagner; Surya Reis; Sung Won Kim; Edward B Holson; Stephen J Haggarty; Jacob M Hooker
Journal:  J Med Chem       Date:  2014-09-18       Impact factor: 7.446

10.  In Vivo 6-([18F]Fluoroacetamido)-1-hexanoicanilide PET Imaging of Altered Histone Deacetylase Activity in Chemotherapy-Induced Neurotoxicity.

Authors:  Nobuyoshi Fukumitsu; Skye Hsin-Hsien Yeh; Leo Garcia Flores Ii; Uday Mukhopadhyay; Daniel Young; Kazuma Ogawa; Hwan-Jeong Jeong; William Tong; Juri G Gelovani
Journal:  Contrast Media Mol Imaging       Date:  2018-03-20       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.